Introduction

This page provides a comprehensive analysis of the known insider trading history of Eric Easom. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Eric Easom has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US: / AN2 THERAPEUTICS Chief Executive Officer, Director 256,380
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Eric Easom. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Eric Easom as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-03 2025-06-02 4 ANTX AN2 Therapeutics, Inc.
Common Stock
P - Purchase 10,000 256,380 4.06 1.07 10,665 273,429
2025-02-28 2025-02-26 4 ANTX AN2 Therapeutics, Inc.
Common Stock
A - Award 145,250 246,380 143.63
2024-11-18 2024-11-18 4 ANTX AN2 Therapeutics, Inc.
Common Stock
P - Purchase 50,000 1,065,766 4.92 1.00 49,970 1,065,127
2024-03-29 2024-03-15 4/A ANTX AN2 Therapeutics, Inc.
Common Stock
A - Award 99,000 101,130 4,647.89
2024-03-18 2024-03-15 4 ANTX AN2 Therapeutics, Inc.
Common Stock
A - Award 99,000 101,130 4,647.89
2024-01-04 2024-01-02 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -2,777 2,130 -56.59 20.09 -55,802 42,801
2023-05-15 2023-05-15 4 ANTX AN2 Therapeutics, Inc.
Common Stock
P - Purchase 10,000 1,015,766 0.99 5.38 53,770 5,461,774
2022-11-14 2022-11-14 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -23 4,907 -0.47 15.04 -346 73,801
2022-11-14 2022-11-10 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -4,413 4,930 -47.23 15.32 -67,628 75,551
2022-11-09 2022-11-09 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -10,111 4,907 -67.33 15.61 -157,847 76,605
2022-11-09 2022-11-08 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -1,255 15,018 -7.71 16.38 -20,559 246,019
2022-11-09 2022-11-08 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -5,800 16,273 -26.28 15.41 -89,388 250,795
2022-11-07 2022-11-07 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -2,036 4,907 -29.32 16.72 -34,036 82,031
2022-11-07 2022-11-07 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -10,167 6,943 -59.42 15.90 -161,705 110,428
2022-11-07 2022-11-04 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -8,828 17,110 -34.04 15.80 -139,474 270,323
2022-11-07 2022-11-03 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -3,083 25,938 -10.62 16.02 -49,376 415,410
2022-11-07 2022-11-03 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -11,082 29,021 -27.63 15.67 -173,683 454,832
2022-11-02 2022-11-02 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -1,544 4,907 -23.93 15.07 -23,263 73,931
2022-11-02 2022-10-31 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -2,688 6,451 -29.41 15.39 -41,363 99,267
2022-10-28 2022-10-28 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -1,683 4,907 -25.54 15.09 -25,392 74,035
2022-10-28 2022-10-27 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -924 6,590 -12.30 15.36 -14,190 101,203
2022-10-26 2022-10-26 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -1,678 4,907 -25.48 15.10 -25,342 74,108
2022-10-26 2022-10-25 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -534 6,585 -7.50 16.20 -8,652 106,690
2022-10-26 2022-10-25 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -4,272 7,119 -37.50 15.69 -67,020 111,685
2022-10-26 2022-10-24 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -2,866 11,391 -20.10 16.17 -46,344 184,194
2022-10-24 2022-10-21 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -2,350 4,907 -32.38 16.69 -39,232 81,919
2022-10-24 2022-10-21 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -11,601 7,257 -61.52 16.29 -189,008 118,234
2022-10-24 2022-10-20 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -31 18,858 -0.16 17.15 -532 323,324
2022-10-24 2022-10-20 4 ANTX AN2 Therapeutics, Inc.
Common Stock
S - Sale X -7,262 18,889 -27.77 16.68 -121,140 315,095
2022-05-16 2022-05-12 4 ANTX AN2 Therapeutics, Inc.
Stock Option (right to buy)
A - Award 225,000 225,000
2022-03-31 2022-03-29 4 ANTX AN2 Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -4,907 0 -100.00
2022-03-31 2022-03-29 4 ANTX AN2 Therapeutics, Inc.
Common Stock
C - Conversion 4,907 4,907
2022-03-24 3 ANTX AN2 Therapeutics, Inc.
Common Stock
1,099,997
2022-03-24 3 ANTX AN2 Therapeutics, Inc.
Common Stock
194,116
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)